Patients who received chemotherapy, actively smoked and drank alcohol, and were diagnosed with head and neck cancer reported significantly higher rates of opiate use, according to study results presented at the American Society of Clinical Oncology (ASCO) 2018 Palliative and Supportive Care Symposium.
Moreover, the researchers found that 70 percent of patients with cancer used opiates after radiation, and survivors who were treated with radiation for more than four weeks had higher rates of opiate use just one year after finishing treatment.
Opioids are commonly prescribed for the management of moderate to severe chronic pain experienced by patients undergoing treatment for cancer, yet few statistics are available to assess how patients with cancer are affected by prescription opioid use. “We don’t know how many cancer patients died from prescription opiates and there is little published data about their prescribing patterns,” the researchers wrote.
To add to the body of knowledge around opioid use in patients with cancer, investigators from the University of Texas Southwestern Medical Center (UTSW) analyzed opioid prescription data from 6,424 patients with lung, breast and head and neck cancer to assess their demographics, cancer type, treatment modality, concurrent medicines, substance abuse history and survival.
The researchers saw widespread use among genders, with 76 percent of 2,112 men and 67 percent of 4,307 women who reported to use these medications, of which 8 percent had three or more different opiates prescribed. Hydrocodone was the most commonly used (67 percent), followed by morphine (12 percent), fentanyl (9 percent), oxycodone (7 percent), and hydromorphone (6 percent).
In total, 18.7 percent of women and 15.9 percent of men received gabapentin — a neuropathic pain reliever that is commonly prescribed to those addicted or at risk of addiction to opioids.
Of the 850 patients who received chemotherapy and radiation, 696 required opiates (82 percent) compared to 68 percent of those who did not receive chemotherapy. Patients with head and neck cancer reported the highest rate of opioid abuse (77 percent) compared with those with breast (65 percent) or lung cancer (70 percent).
Lastly, the researchers found that of the 2,643 patients who used alcohol, 2,001 received opiates (76 percent) compared to 67 percent of those who did not use alcohol. Among active smokers, 76 percent used opiates versus 67 percent of those who never smoked.
Social Habits, Cancer Type and Treatment Impact Increased Rates of Opioid Use
Mindy Waizer
Patients who received chemotherapy, actively smoked and drank alcohol, and were diagnosed with head and neck cancer reported significantly higher rates of opiate use, according to study results presented at the American Society of Clinical Oncology (ASCO) 2018 Palliative and Supportive Care Symposium.
Patients who received chemotherapy, actively smoked and drank alcohol, and were diagnosed with head and neck cancer reported significantly higher rates of opiate use, according to study results presented at the American Society of Clinical Oncology (ASCO) 2018 Palliative and Supportive Care Symposium.
Moreover, the researchers found that 70 percent of patients with cancer used opiates after radiation, and survivors who were treated with radiation for more than four weeks had higher rates of opiate use just one year after finishing treatment.
Opioids are commonly prescribed for the management of moderate to severe chronic pain experienced by patients undergoing treatment for cancer, yet few statistics are available to assess how patients with cancer are affected by prescription opioid use. “We don’t know how many cancer patients died from prescription opiates and there is little published data about their prescribing patterns,” the researchers wrote.
To add to the body of knowledge around opioid use in patients with cancer, investigators from the University of Texas Southwestern Medical Center (UTSW) analyzed opioid prescription data from 6,424 patients with lung, breast and head and neck cancer to assess their demographics, cancer type, treatment modality, concurrent medicines, substance abuse history and survival.
The researchers saw widespread use among genders, with 76 percent of 2,112 men and 67 percent of 4,307 women who reported to use these medications, of which 8 percent had three or more different opiates prescribed. Hydrocodone was the most commonly used (67 percent), followed by morphine (12 percent), fentanyl (9 percent), oxycodone (7 percent), and hydromorphone (6 percent).
In total, 18.7 percent of women and 15.9 percent of men received gabapentin — a neuropathic pain reliever that is commonly prescribed to those addicted or at risk of addiction to opioids.
Of the 850 patients who received chemotherapy and radiation, 696 required opiates (82 percent) compared to 68 percent of those who did not receive chemotherapy. Patients with head and neck cancer reported the highest rate of opioid abuse (77 percent) compared with those with breast (65 percent) or lung cancer (70 percent).
Lastly, the researchers found that of the 2,643 patients who used alcohol, 2,001 received opiates (76 percent) compared to 67 percent of those who did not use alcohol. Among active smokers, 76 percent used opiates versus 67 percent of those who never smoked.
Cancer's Terror in the Night
April 7th 2024Cancer is an emotionless assassin that can attack us and the ones we love most.
Read More
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
Listen
Jason Kelce Honors Trainer With Cancer, ESPN Reporter Died of Cancer and More
March 8th 2024From Jason Kelce honoring the team trainer who has been diagnosed with cancer to deaths in the sports reporting and music world, here’s what’s happening in the oncology space this week.
Read More
Author, Five-Time Cancer Survivor Shares His Experiences in New Book
August 10th 2023Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Listen
‘Striking’ Findings for Substance Use Disorders in Some Cancer Types
February 7th 2024Substance use disorders, such as alcohol use disorder, were found to be more prevalent among survivors of specific cancer types, according to research.
Read More
FDA OKs Trial of TIL Therapy in Skin, Head and Neck and Lung Cancers
December 5th 2023The Food and Drug Administration gave the green light to a phase 1/2 trial of KSQ-001EX for patients with melanoma, head and neck squamous cell carcinoma and non-small cell lung cancer.
Read More
Cancer's Terror in the Night
April 7th 2024Cancer is an emotionless assassin that can attack us and the ones we love most.
Read More
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
Listen
Jason Kelce Honors Trainer With Cancer, ESPN Reporter Died of Cancer and More
March 8th 2024From Jason Kelce honoring the team trainer who has been diagnosed with cancer to deaths in the sports reporting and music world, here’s what’s happening in the oncology space this week.
Read More
Author, Five-Time Cancer Survivor Shares His Experiences in New Book
August 10th 2023Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Listen
‘Striking’ Findings for Substance Use Disorders in Some Cancer Types
February 7th 2024Substance use disorders, such as alcohol use disorder, were found to be more prevalent among survivors of specific cancer types, according to research.
Read More
FDA OKs Trial of TIL Therapy in Skin, Head and Neck and Lung Cancers
December 5th 2023The Food and Drug Administration gave the green light to a phase 1/2 trial of KSQ-001EX for patients with melanoma, head and neck squamous cell carcinoma and non-small cell lung cancer.
Read More